Evanium Raises $2.4M in Funding Round Backed by FoodLabs and Feast Ventures

Why It Matters

The breakthrough offers a clean‑label, high‑performance alternative to synthetic emulsifiers, unlocking higher efficacy for nutraceuticals and expanding market opportunities. It positions Evanium as a strategic technology partner for brands seeking natural, high‑bioavailability ingredients.

Key Takeaways

• Evanium raised €2.2M (~$2.4M) to scale Optisolv technology.
• Dual‑coating system boosts solubility >1,000× and digestion >170× for curcumin.
• Optisolv uses all‑natural cyclodextrin core and sunflower‑lecithin shell.
• Technology targets food, supplement, nutricosmetics, and pharma markets.

Pulse Analysis

The nutraceutical sector has long wrestled with the low water solubility of many plant‑derived compounds, which translates into poor intestinal absorption and limited efficacy. Consumers increasingly demand clean‑label products, yet manufacturers often resort to synthetic surfactants to improve bioavailability, compromising the natural appeal. According to market research, the global dietary‑supplement market is projected to exceed $200 billion by 2028, driving a search for technologies that can deliver higher potency without additives. Evanium’s recent €2.2 million raise signals investor confidence that such a solution is commercially viable.

Optisolv tackles the problem with a dual‑encapsulation architecture: an inner cyclodextrin ring masks the hydrophobic molecule, while an outer shell of sunflower lecithin and starch provides a natural barrier. This configuration prevents crystallization, enhances solubility, and protects heat‑sensitive actives during processing. In vitro tests on curcumin demonstrated more than a 1,000‑fold increase in solubility and a 170‑fold boost in digestive uptake compared with conventional hydrochloride salts. With four patented ingredients already launched, the platform offers a scalable, all‑natural alternative to conventional emulsifiers.

The infusion of Optisolv into food, supplement, nutricosmetics and pharmaceutical pipelines could reshape formulation strategies, allowing brands to lower dosages while maintaining efficacy. Clinical trials slated for later this year will provide the regulatory data needed to substantiate health claims, a critical step for market adoption. By exhibiting at Vitafoods, Evanium aims to secure strategic partnerships and accelerate commercialization across Europe and North America. If the technology lives up to its early results, it may set a new benchmark for natural bioavailability, prompting competitors to invest in similar clean‑label delivery systems.

Deal Summary

Evanium, a developer of dual‑coating encapsulation technology for nutraceuticals, announced a €2.2 million ($2.4 million) funding round backed by FoodLabs and Feast Ventures. The capital will be used to scale its Optisolv platform, advance clinical studies and expand partnerships across food, supplement and pharma markets.